Plasma Aminopeptidase Activities in Parkinson's Disease

Abstract

Parkinson's disease (PD) is an age-related neurodegenerative disease characterized by a progressive motor disorder, but frequently is accompanied by autonomic symptoms such as hypotension. Together with the decrease of dopamine, significant decreases in aminopeptidase activities have been reported in PD brains. However, up to date there are no studies about changes of aminopeptidase activities in plasma of PD patients. We studied plasma activities of alanyl-, aspartyl-(AspAP), cystinyl-(CysAP) and glutamyl-aminopeptidase (GluAP) in two groups of subjects: control (n=41) and PD (n=48). Plasma activities of AspAP, CysAP, and GluAP showed significant decreases of 24.9% (p<0.05), 39.4% (p<0.01) and 33.3% (p<0.01), respectively, in PD group. These aminopeptidases are involved in the metabolism of circulating peptides such as the ones of the renin-angiotensin system. The importance of aminopeptidases in striatal dopamine content and in neuroendocrine system in PD is discussed.

Key words

Aminopeptidases - renin-angiotensin system - Parkinson's disease

References

• 1 Zhang J, Goodlett DR, Montine TJ. Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases.  J Alzheimers Dis. 2005;  8 377-386
• 2 Micieli G, Tosi P, Marcheselli S, Cavallini A. Autonomic dysfunction in Parkinson's disease.  Neurol Sci. 2003;  24 ((Suppl 1)) S32-S34
• 3 Gonzalez De Aguilar JL, Rene F, Dupuis L, Loeffler JP. Neuroendocrinology of neurodegenerative diseases. Insights from transgenic mouse models.  Neuroendocrinology. 2003;  78 244-252
• 4 Banegas I, Ramirez M, Vives F, Alba F, Segarra AB, Duran R, De Gasparo M, Prieto I. Aminopeptidase activity in the nigrostriatal system and prefrontal cortex of rats with experimental hemiparkinsonism.  Horm Metab Res. 2005;  37 53-55
• 5 Banegas I, Prieto I, Vives F, Alba F, Duran R, Segarra AB, de Gasparo M, Ramirez M. Plasma aminopeptidase activities in rats after left and right intrastriatal administration of 6-hydroxydopamine.  Neuroendocrinology. 2004;  80 219-224
• 6 Mantle D, Falkous G, Ishiura S, Perry RH, Perry EK. Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.  J Neurol Sci. 1995;  131 65-70
• 7 Agil A, Durán R, Barrero F, Morales B, Araúzo M, Alba F, Miranda MT, Prieto I, Ramírez M, Vives F. Plasma lipid peroxidation in sporadic Parkinson's disease.  J Neurol Sci. 2006;  240 31-36
• 8 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.  Anal Biochem. 1976;  72 248-254
• 9 Li ST, Dendi R, Holmes C, Goldstein DS. Progressive loss of cardiac sympathetic innervation in Parkinson's disease.  Ann Neurol. 2002;  52 220-223
• 10 Otake K, Oiso Y, Mitsuma T, Hirooka Y, Adachi K. Hypothalamic dysfunction in Parkinson's disease patients.  Acta Med Hung. 1994;  50 3-13
• 11 Segarra AB, Ramirez M, Banegas I, Hermoso F, Vargas F, Vives F, Alba F, de Gasparo M, Prieto I. Influence of thyroid disorders on kidney angiotensinase activity.  Horm Metab Res. 2006;  38 48-52
• 12 Jenkins TA, Wong JY, Howells DW, Mendelsohn FA, Chai SY. Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in the MPTP-treated mouse.  J Neurochem. 1999;  73 214-219

Correspondence